Sandyk R
NeuroCommunication Research Laboratories, Danbury, CT 06811, USA.
Int J Neurosci. 1995 Mar;81(1-2):67-82. doi: 10.3109/00207459509015299.
Neuropsychological studies have demonstrated that Parkinson's disease (PD) is associated with various cognitive deficits ultimately leading in about 30% of patients to the development of dementia. These studies have demonstrated also a greater decrement of right hemispheric functions with visuospatial deficits occurring in up to 90% of PD patients. The Rey-Osterrieth Complex Figure (ROCF) Test has been employed in the assessment of right hemispheric functions and particularly for the evaluation of visuoconstructive abilities and short-term visual memory. I have demonstrated recently that external application of electromagnetic fields (EMFs) in the picotesla (pT) range intensity is an effective nonpharmacological modality in the management of the motor and cognitive deficits of Parkinsonism. In the present communication I present 3 fully medicated nondemented PD patients (mean age: 68 +/- 8.1 yrs; mean duration of illness: 9.0 +/- 4.0 yrs; mean disability on the Hoehn and Yahr scale: 3) who were tested on the ROCF Test before and after a series of treatments with EMFs. In response to the administration of EMFs the group demonstrated a mean of 23.1 +/- 13.6% improved performance on copy of the ROCF and a 39.3 +/- 13.4% improvement of short-term recall of the ROCF. These findings demonstrate that treatment with pT EMFs improves deficits in visuospatial functions and visual memory in Parkinsonism which usually remain unaffected during standard treatment with dopaminergic pharmacotherapy.
神经心理学研究表明,帕金森病(PD)与多种认知缺陷相关,最终约30%的患者会发展为痴呆。这些研究还表明,右半球功能衰退更为明显,高达90%的PD患者存在视觉空间缺陷。雷-奥斯特里茨复杂图形(ROCF)测试已被用于评估右半球功能,特别是用于评估视觉构建能力和短期视觉记忆。我最近证明,在皮特斯拉(pT)范围内强度的电磁场(EMF)外部应用是治疗帕金森病运动和认知缺陷的一种有效的非药物方法。在本报告中,我介绍了3名完全接受药物治疗且未患痴呆的PD患者(平均年龄:68±8.1岁;平均病程:9.0±4.0年;Hoehn和Yahr量表平均残疾程度:3级),他们在接受一系列EMF治疗前后接受了ROCF测试。在接受EMF治疗后,该组在ROCF复制测试中的表现平均提高了23.1±13.6%,在ROCF短期回忆测试中的表现提高了39.3±13.4%。这些发现表明,pT EMF治疗可改善帕金森病患者的视觉空间功能和视觉记忆缺陷,而这些缺陷在多巴胺能药物标准治疗期间通常不受影响。